openPR Logo
Press release

Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018

Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline

Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.

Download the sample report at: https://www.pharmaproff.com/request-sample/1025

A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated FAP (AFAP), Gardner syndrome, and Turcot syndrome.

Get the detailed analysis at: https://www.pharmaproff.com/report/fap-therapeutics-pipeline-analysis

The risk factors associated with FAP are obesity, physical inactivity, smoking, high alcohol and red meat consumption. TherapyX Inc. is in the process of developing FAPXIL as a small molecule with oral route of administration for the treatment of FAP. Other than this Cellix Bio Private Limited is also in the process of drug development for FAP.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1025

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018 here

News-ID: 1750394 • Views: 189

More Releases for FAP

Fibroblast Activation Protein Inhibitors Market to Witness a Pronounce Growth by …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market Dynamics, Forecast, Analysis and …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market with Current Trends Analysis, 20 …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market by Key Players, Growth, Regions …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
01-25-2017 | Health & Medicine
TMR
Fibroblast Activation Protein Inhibitors Market - Evolving Technology, Trends an …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market : Huge Opportunities Lie In Deve …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed